ClinicalTrials.gg
Not yet recruitingNCT06047015Updated Aug 9, 2024

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

A Phase 1/2 interventional study of IRE plus checkpoint inhibitor and IRE plus Checkpoint Inhibitor plus CpG-ODN in Liver Metastasis Colon Cancer, sponsored by University of Saskatchewan. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by University of Saskatchewan · Phase 1/2, Interventional, and Treatment

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Study summary

The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis). The main questions it aims to answer are:

  1. to document the rate of complications associated with combining IRE with immune boosting drugs.
  2. After one liver metastasis is treated with IRE and immune boosting drugs, what is the change in the size of the non-IRE-treated liver metastases?
  3. What is the immune response (measured in a blood sample) when IRE is combined with one or two types of immune boosting drugs?
Read the detailed description

Single-centre pilot study of the use of IRE for the treatment of 12 patients with unresectable colorectal liver metastases to assess feasibility and gain preliminary data to inform the design of a larger study.

02

Conditions studied

  • Liver Metastasis Colon Cancer
03

In context

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

This study's planned enrollment of 12 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

University of Saskatchewan is the lead sponsor of 243 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -proven colorectal liver with at least one measuring \< 3.5 cm in diameter and accessible to percutaneous IRE such that a complete ablation of the lesion is possible.
  2. Prior resection of the colorectal cancer primary.
  3. The imaging has been reviewed in multi-disciplinary Rounds and the colorectal liver metastases have been deemed unresectable.
  4. Patient has undergone chemotherapy and has not converted to resectable disease.
  5. Radiologic evidence of stable disease for at least two months on systemic therapy for colorectal cancer (may have had prior partial response or disease progression)
  6. Microsattelite instability (MSI)-stable or mismatch-proficient tumors
  7. Patient has HLA phenotype of Human Leukocyte Antigen (HLA) A1 or HLA A2.
  8. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Size of the being treated with IRE > 3.2 cm or \< 2 cm.
  2. Size of any non-IRE-treated liver metastasis > 4 cm
  3. Pregnancy
  4. Major comorbid disease
  5. Active disease
  6. Bone or brain or peritoneal metastases.
  7. MSI High disease
  8. Patients with cardiac arrhythmia other than rate controlled atrial fibrillation.
  9. Metal implant that cannot be removed within 10 cm of the area to be treated.
  10. Peritoneal disease.
  11. Poor performance status
  12. Cirrhosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    IRE plus Checkpoint Inhibitor

    Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment. IRE is performed in the CT scanner. Patients will receive a general anesthetic, and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al.

    Combination Product: IRE plus checkpoint inhibitor

  • Experimental
    IRE plus Checkpoint Inhibitor plus CpG Oligodeoxynucleotides (CpG-ODN)

    Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG-ODN solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug. IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al.

    Combination Product: IRE plus Checkpoint Inhibitor plus CpG-ODN

Interventions

  • Combination productIRE plus checkpoint inhibitor

    Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.

  • Combination productIRE plus Checkpoint Inhibitor plus CpG-ODN

    Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug. IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al.

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Complications

    Complications (Clavien-Dindo classification of complications) at 30 days. The Clavien-Dindo Classification of Complications involves assigning a numbered classification to each complication, from 1-5, with 1 being a complication without need for any intervention required to 5 which is death of the patient. (a higher number indicates a higher severity). This is a validated measure in use for over 25 years.

    Time frame: 30 days

  2. Complications

    Complications (Clavien-Dindo classification of complications) at 90 days. The Clavien-Dindo Classification of Complications involves assigning a numbered classification to each complication, from 1-5, with 1 being a complication without need for any intervention required to 5 which is death of the patient. (a higher number indicates a higher severity). This is a validated measure in use for over 25 years.

    Time frame: 90 days

  3. Abscopal effect: percent change in non-treated colorectal liver metastasis.

    Two radiologists (one diagnostic and the other interventional) will examine the scans of all patients. They will select a colorectal metastasis from the scan just before the intervention that is between 2-3.2 cm in maximal diameter, accessible to percutaneous ablation, and treatable according to the interventional radiologist's opinion. Another metastasis, with a maximal diameter of less than 4 cm, will be selected to monitor for the abscopal effect (reduction in size of a colorectal liver metastasis that was not treated with IRE). After 3 months, the radiologists will review the imaging again. They will assess the treatment mass area for any contrast uptake indicating incomplete ablation. The second metastasis will be measured in the same dimensions as before treatment. The difference in maximal diameter of the second metastasis will be calculated as (diameter before IRE - diameter after IRE) / diameter before IRE and expressed as a percentage.

    Time frame: 3 months from the time of IRE

Secondary outcomes

  1. Tumor-specific immune response: distribution on flow-cytometry plot

    Distribution of Carcinoembryonic (CEA)-specific CD8+ T cells, CD4+ T cells, type-1 and 2 macrophages (M1 and M2), regulatory T (Treg) cells on the flow-cytometry plot.

    Time frame: Day 8

  2. Tumor-specific immune response: serum cytokine concentrations

    Interleukin(IL)-2, Interferon (IFN)-α, IFN-γ, IL-10 and Transforming Growth Factor (TGF)-β.

    Time frame: Day 8

  3. Tumor-specific immune response: distribution on flow-cytometry plot.

    Distribution of Carcinoembryonic (CEA)-specific CD8+ T cells, CD4+ T cells, type-1 and 2 macrophages (M1 and M2), regulatory T (Treg) cells on the flow-cytometry plot.

    Time frame: Day 14

  4. Tumor-specific immune response: serum cytokin concentrations

    Interleukin(IL)-2, Interferon (IFN)-α, IFN-γ, IL-10 and Transforming Growth Factor (TGF)-β.

    Time frame: Day 14

  5. Tumor-specific immune response: distribution on flow-cytometry plot.

    Distribution of Carcinoembryonic (CEA)-specific CD8+ T cells, CD4+ T cells, type-1 and 2

    Time frame: Day 30

  6. Tumor-specific immune response

    Interleukin(IL)-2, Interferon (IFN)-α, IFN-γ, IL-10 and Transforming Growth Factor (TGF)-β.

    Time frame: Day 30

  7. Progression-free survival

    Progression-free survival will be determined based on the CT scan conducted after one year. To prove the absence of progression, there should be no contrast uptake in the area that was treated with IRE one year prior, AND the maximal diameter of the second lesion (not treated with IRE) should have increased by less than 10%.

    Time frame: 1 year

  8. Progression-free survival

    Progression-free survival will be determined based on the CT scan conducted after two years. To prove the absence of progression, there should be no contrast uptake in the area that was treated with IRE two years prior, AND the maximal diameter of the second lesion (not treated with IRE) should have increased by less than 10%

    Time frame: 2 years

  9. Quality of life questionnaire

    Quality of life using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire, a 27-item questionnaire, each item to be rated 1-5. The scores are totalled and total scores range from 0-108, with higher scores indicating a higher quality of life.

    Time frame: baseline

  10. Quality of life questionnaire

    Quality of life using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire, a 27-item questionnaire, each item to be rated 1-5. The scores are totalled and total scores range from 0-108, with higher scores indicating a higher quality of life.

    Time frame: 12 weeks

  11. Quality of life questionnaire

    Quality of life using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire, a 27-item questionnaire, each item to be rated 1-5. The scores are totalled and total scores range from 0-108, with higher scores indicating a higher quality of life.

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2027, 29 months later.

Of 59 phase 1/2 interventional studies under Colonic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 93. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Sep 21, 2023
StartEst.
Jul 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06047015
Responsible party
Mike Moser (Associate Professor of Surgery, University of Saskatchewan) — Principal investigator
First posted
Sep 21, 2023
Start date
Jul 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 9, 2024

Study contacts

Mike AJ Moser, MD, MSc
Contact
mike.moser@usask.ca
306-655-5319
Shahid Ahmed, MD
Contact
shahid.ahmed@saskcancer.ca
306-655-2630

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion